Study finds a new vulnerability in the virus to search for an HIV vaccine


NIH team discovered a new target in the search for HIV vaccine

A model VRC34.01 antibody (green and yellow) bound to the fusion peptide (red) in a peak on the surface of HIV (gray). Credit: NIAID

A team led by scientists at the National Institutes of Health (NIH) reported a trifecta investigation. They found a new point of vulnerability for an HIV vaccine with a broadly neutralizing antibody that binds to that target site and as empede antibody oo virus to infect a cell. The study was conducted by scientists in the vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases, NIH part.

The new target is a part called HIV fusion peptide, a chain of eight amino acids that helps the virus to fuse with a cell to infect. The fusion peptide has a much simpler structure than other virus surface points that HIV vaccine scientists have studied over time.


A model VRC34.01 antibody (green and yellow) bound to the fusion peptide (red) in a peak on the surface of HIV (gray). Credit: NIAID

The scientists first examined the blood of HIV-infected people to explore their ability to prevent the virus from infecting other cells. The blood could neutralize HIV but not at the target site of any of the points that were known to fix broadly neutralizing antibodies against HIV (bNAbs).

AIDS-108235Researchers have isolated a powerful bNAb in the blood sample as they called VRC34.01 and discovered that binds to the fusion peptide and a sugar molecule. The scientists then crystallized antibody while he was linked to the virus. This allowed them to describe in detail the atomic level as VRC34.01 HIV attaches to and revealed that the antibody prevents the virus infects a cell by attachment to a key cell surface molecule.

Scientists also relataran which is not unusual for the immune system tries to stop HIV infection in the process of a cell attacking the fusion peptide. When they rastream the blood 24 HIV-infected volunteers, they found that blood samples from ten people showed similar binding sites to VRC34.01.

Researchers are working to create a vaccine to motivate similar antibodies to VRC34.01 antibody to adopt this type of behavior.

The study was published in the journal Science.

12 May 2016 with Carlos Mota information

Translated by Claudio Souza the originalStudy discovers new HIV vaccine targetreviewed by Mara Macedo